Abstract
Background Patients on dialysis have impaired cardiac function, in part due to increased fluid volume and ventricular stress. Restored kidney function through transplantation reduces left ventricular volume in both systole and diastole. Paraoxonase 1 (PON1) is reduced in patients on dialysis, which may be related to their impaired cardiac function. We tested the hypothesis that change in PON1 is associated with changes in left ventricular (LV) end-volume and LV mass after kidney transplantation.
Methods Patients were studied before and 12 months after kidney transplantation. The control group was patients on dialysis not expected to receive a transplant in the next 12 months. Cardiac magnetic resonance imaging was used to measure LV end-diastolic and end-systolic volume and LV mass. PON1 was measured by arylesterase activity and by mass.
Results PON1 mass and activity were not different between the groups at baseline. Both PON1 mass and activity were increased post-kidney transplantation (p<0.0001 for change). The change in PON1 mass (p=0.0062) and PON1 arylesterase activity (p=0.0254) were inversely correlated with the change in NT-proBNP for patients receiving a kidney transplant. However, only the change in the PON1 mass, but not the change in PON1 arylesterase, was inversely correlated with the change in left ventricular volume (ml/m2.7) (p=0.0146 and 0.0114 for diastolic and systolic, respectively) and with the change in hemoglobin (p=0.0042).
Conclusions PON1 mass and activity increase after kidney transplantation. The increase in PON1 mass is consistent with a novel relationship to the increase in hemoglobin and the decrease in LV end-systolic and end-diastolic volume.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Heart and Stroke Foundation of Canada, Grant Number HSFNA7077, and by the Canadian Institutes of Health Research Grant Number MOP-136954. Dr. Yan is supported by a Clinician-Scientist Award from the University of Toronto. Dr. Lakshman Gunaratnam is supported by Schulich new investigator Award, Schulich School of Medicine and Dentistry, Western University, and the KRESCENT/CIHR New Investigator Award.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available upon request.
Abbreviations
- CKD
- chronic kidney disease
- CMR
- cardiac magnetic resonance imaging
- ESKD
- end-stage kidney disease
- HD
- hemodialysis
- HDL
- high density lipoprotein
- LV
- left ventricular
- NT-proBNP
- NT pro-B type natriuretic peptide
- PON1
- paraoxonase 1
- PD
- peritoneal dialysis
